ATNM — Actinium Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $41.10m
- -$6.89m
- $0.09m
Annual cashflow statement for Actinium Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.8 | -33 | -48.8 | -38.2 | -33.9 |
| Depreciation | |||||
| Non-Cash Items | 1.69 | 2.79 | 3.84 | 5.91 | 9.84 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.69 | 38.2 | -3.15 | -0.932 | -0.704 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -20.9 | 8.64 | -47.3 | -33.1 | -24.6 |
| Capital Expenditures | -0.133 | -0.366 | -0.153 | -0.011 | -0.104 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.133 | -0.366 | -0.153 | -0.011 | -0.104 |
| Financing Cash Flow Items | — | — | — | — | -0.207 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 35.2 | 23.1 | 14.9 | 29.3 | -0.217 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.2 | 31.4 | -32.6 | -3.76 | -24.9 |